(Q26785995)

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).

PubMed

volume

6

0 references

issue

5

0 references

page(s)

264-72

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Updated treatment algorithm of pulmonary arterial hypertension.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Riociguat for the treatment of pulmonary arterial hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Treatment of pulmonary arterial hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

31 May 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Macitentan and morbidity and mortality in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622315590757

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549695